Related Experiment Video
Updated: Mar 19, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.3K
[Adaptive drug licensing: A chance for patients?]
1Medizinischer Direktor, SANOFI, Berlin, Germany.
Summary
Accelerated drug approval balances faster access to new treatments against potential safety risks. Open discussion among patients, regulators, and companies is key for fair, benefit-risk balanced decisions.
Area of Science:
- Pharmacoeconomics
- Drug development
- Regulatory science
Background:
- Discussions are ongoing regarding methods to expedite the approval of novel therapeutics, particularly for diseases with significant unmet medical needs.
- Accelerated drug approval presents a trade-off between earlier patient access to treatments and potentially increased safety concerns due to limited long-term clinical trial data and broader patient exposure.
Purpose of the Study:
- To explore the complexities and necessary considerations for accelerating drug approval processes.
- To highlight the importance of balancing the benefits of early drug availability against potential safety risks.
Main Methods:
- This discussion synthesizes current perspectives on drug approval pathways.
- It emphasizes the need for comprehensive evaluation of clinical trial data for reimbursement decisions.
Main Results:
- The process of weighing the benefits against the risks of accelerated drug approval requires careful consideration.
- Sufficient clinical trial data is essential for securing reimbursement for new treatments.
Conclusions:
- A collaborative dialogue involving patients, regulatory bodies, health technology assessment (HTA) institutions, and pharmaceutical firms is crucial.
- Patients stand to gain from a fair and balanced approach to accelerated drug approval that prioritizes both efficacy and safety.
Keywords:
ArzneimittelsicherheitArzneimittelzulassungDrug approvalHTA InstitutionenHTA organizationsZulassungsbehördenaccelerated approvaladaptive licensingbeschleunigte Arzneimittelzulassungdrug regulatory agenciesdrug safetymalignes Melanommetastatic melanomaprimary hypercholesterolemiaprimäre HypercholesterinämieMore Related Videos
Related Concept Videos
01:17Drug Nomenclature
3.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.6K
01:25Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
01:26Drug Discovery: Overview
12.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.8K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
345
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
345
01:26Drug Administration and Therapy Phases: Overview
1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
60
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60